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Highlights  
 Presenteeism is rarely included in full economic evaluations, but is more often included in 
cost of illness studies 
 There are a variety of methods available for generating estimates of presenteeism and valuing 
these, but little consistency across studies 
 More methodological work is required to generate better estimates of presenteeism, 
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Abstract  
Introduction 
Given the significant costs of reduced productivity (presenteeism) in comparison to absenteeism, and 
overall societal costs, presenteeism has a potentially important role to play in economic evaluations. 
However, in practice these costs are often excluded. This paper provides a comprehensive overview 
of the current state of practice in the valuation methods and impact of presenteeism in cost of illness 
studies and economic evaluations.  
Methods 
A structured systematic review was carried out to explore (i) the extent to which presenteeism has 
been applied in cost of illness studies and economic evaluations and (ii) the overall impact of 
including presenteeism on overall costs and outcomes. Potential articles were identified by searching 
Medline, PsycINFO and NHS EED databases.  A standard template was developed and used to extract 
information from economic evaluations and cost of illness studies incorporating presenteeism costs. 
Results 
A total of 28 studies were included in the systematic review which also demonstrated that 
presenteeism costs are rarely included in full economic evaluations. Estimation and monetisation 
methods differed between the instruments. The impact of disease on presenteeism whilst in paid work 
is high.  
Conclusions  
The potential impact of presenteeism costs needs to be highlighted and greater consideration should 
be given to including these in economic evaluations and cost of illness studies. The importance of 
including presenteeism costs when conducting economic evaluation from a societal perspective 
should be emphasised in national economic guidelines and more methodological work is required to 
improve the practical application of presenteeism instruments to generate productivity cost estimates.     
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INTRODUCTION 
Productivity costs can be defined as ‘Costs associated with production loss and replacement costs due 
to illness, disability and death of productive persons, both paid and unpaid’ [1]. According to 
neoclassical theory, the idea of productivity is part of a production function, with labour as a key input 
contributing to output. Productivity therefore is a measure of output per unit of input [2]. Detailed 
theoretical and methodological discussions on this concept have been extensively discussed elsewhere 
[2].In the context of this paper, productivity loss due to sickness refers to output loss resulting from 
work absence and/or reduced labour input due to sickness (that is, it is not concerned with lost income 
from the individual perspective, but with lost output from the societal perspective). Productivity costs 
have an important, yet controversial, role in economic evaluation. This is particularly the case when 
the evaluation is performed from a societal perspective. There have been strong arguments in favour 
of adopting a societal perspective within economic evaluations [3, 4], although there is no theoretical 
consensus on the most appropriate perspective [5, 6]. Some have argued that adopting a narrower 
perspective – such as a specific provider or institution, patient or third-party provider could lead to 
biased health policies for society as a result of ignoring important cost categories outside the 
healthcare sector [4]. Comprehensive discussions on the issue of perspectives are addressed elsewhere 
in more detail [3, 4]. In theory when adopting a societal perspective, all relevant costs and 
consequences to whomsoever they accrue should be considered within the evaluation, including 
productivity costs. It is important to note that there have been various debates about the inclusion of 
productivity costs in economic evaluations. These debates include whether productivity costs should 
be included on the cost or outcome side, and the methods used to measure and value productivity 
costs, especially in relation to paid work [2, 7-9]. The inclusion of productivity costs has mostly been 
limited to the context of paid work which is the broad focus of this paper. Another issue often ignored 
in productivity costs that will not be covered in this paper relates to unpaid work. Detailed 
methodological and practical discussions in relation to unpaid work are provided elsewhere [10].  
 
Paid work broadly consists of productivity loss to society as a result of absence from work 
(absenteeism) or working with limitations due to illness (presenteeism). Compared to absence from 
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work, the evidence suggests that presenteeism generates significantly higher cost estimates than 
absenteeism [11]. Productivity costs related to presenteeism seem to be rarely considered in economic 
evaluations [12], although there is limited evidence on this. Ignoring these costs could significantly 
underestimate the value of interventions that reduce limitations at work due to illness. 
The exclusion of societal costs related to presenteeism in economic evaluations may be explained by 
several factors. Firstly, an overview of most national economic guidelines, where a societal 
perspective is recommended, shows there tends to be a bias towards including absenteeism costs, but 
not presenteeism costs [13]. Secondly, the theoretical literature suggests a lack of consensus on the 
most appropriate instrument for measuring presenteeism, and on the valuation methods for generating 
monetary estimates from existing measures. Both are required if presenteeism costs are to be included 
in economic evaluation [14, 15]. A scoping review [16] of existing productivity loss measurement 
instruments reported in various systematic reviews identified a total of 24 instruments [2, 15, 17-26]. 
The most commonly reported were the Work limitations Questionnaire (WLQ)[27] , Health and Work 
Performance Questionnaire (HPQ)[28] , Work productivity and Activity impairment questionnaire 
(WPAI)[29] , Health and Labour Questionnaire (HLQ)[30] , and Health and Work Questionnaire 
(HWQ)[31] . These instruments differ both in the ways that presenteeism is measured and valued. 
Inevitably, this will impact on comparability between studies that use different instruments.  
The evidence on whether, and how, presenteeism costs are estimated in economic studies and on the 
size of these costs, also appears to be limited. Previous literature has involved assessing 
appropriateness of existing instruments [18, 22] and valuation methods [15, 20] but not studied which 
instruments have been used to estimate presenteeism in practice in the context of cost of illness 
studies or economic evaluation. This review goes further by assessing which instruments have been 
used in practice, and how, to estimate presenteeism costs. A 2009 review of presenteeism considered 
the impact of presenteeism on the total cost of health conditions from a narrow employer perspective, 
but did not examine the methods used in economic studies [25].  The review found that job-related 
reduced productivity was a major component of total employer costs for various health conditions, but 
was not able to assess presenteeism instruments used in practice, and how, to estimate presenteeism 
costs at the time. The more up-to-date review presented here aims to extend the earlier review by 
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investigating two related research questions in relation to this area: (i) what methods are economic 
studies using to estimate presenteeism in current practice? and (ii) what is the impact of presenteeism 
on the total costs of interventions and health conditions in existing economic studies?  
 
METHODS 
A systematic review of published applied economic studies, comprising cost of illness studies and 
economic evaluations, was conducted to explore the research aims.  
Search strategy 
Searches were conducted in MEDLINE (OVID), PsycINFO (OVID), and the specific health 
economics database NHS Economic Evaluation (NHS EED), and limited to studies published up to 
31st August 2015 with no starting date limitation. The search strategies used were based on the 
following key pre-defined search keywords: ‘presenteeism’ OR ‘reduced productivity’ OR 
‘productivity costs OR ‘lost productivity’ OR ‘work limitations’ OR ‘work productivity’ OR ‘work 
performance’, subsequently in conjunction with the terms ‘cost and cost analysis’ or ‘cost-
effectiveness analysis’ or ‘cost-utility analysis’. Where relevant, MeSH headings were exploded. The 
list of study titles was supplemented by a bibliographic review of papers included in the review, and 
through searching other electronic sources such as Google Scholar for articles from academics known 
in this area. 
Study selection 
Studies were included only if they: 1) were original applied cost of illness studies or economic 
evaluations; 2) incorporated costs related to presenteeism, and described the methods for doing so; 
and 3) were written in English.  After excluding duplicates, the abstracts of the remaining articles 
were assessed in terms of these inclusion criteria.  Full-texts were obtained for all studies that 
appeared to meet the inclusion criteria at this point, and were read to make a final decision on study 
inclusion.  Initial study selection was performed by JK, and where there was any ambiguity about 
inclusion/exclusion, the study was discussed by the whole research team before a final decision was 
made.  
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Data extraction and analysis  
A data extraction form was developed to extract systematic information on study characteristics 
related to study country, publication year, type of economic evaluation and disease area. 
Methodological characteristics of interest included type of instrument, recall period, productivity loss 
reported, type of instrument, monetisation algorithm used (if available), and the proportion of 
presenteeism costs in relation of absenteeism and/or overall total costs. Data extraction was performed 
by JK.  Narrative synthesis was used to summarise and explain the findings. 
RESULTS 
Study selection 
In total 610 potentially relevant articles were identified, of which 16 were excluded on the grounds 
they were duplicates. Of the remaining 594 articles, 538 did not meet the inclusion criteria on the 
basis of the abstract, leaving 56 papers that were read in full.  Of these, 35 did not incorporate 
presenteeism, or were reviews or protocols and were subsequently excluded. Seven additional articles 
were identified through searching references of studies identified from the databases and other 
electronic sources. This resulted in a total of 28 studies that met the criteria for the review.  
Study Characteristics 
A summary of the 28 studies included in the review is presented in Table 1. The majority (57%) of 
studies identified were conducted in the United States (US). The others were from the Netherlands 
[32, 33], from Canada [34-36], the United Kingdom (UK) [37-39], Sweden [40], and Thailand [41].  
There were two multi-country studies, with one set across Australia, US and the UK [42], and the 
other reporting cost estimates from 8 European countries including Germany, Italy, Lithuania, the 
Netherlands, Luxembourg, Austria, France, and Spain [43].   
 
The studies evaluated a wide range of diseases and varied from national survey based costing studies 
covering various conditions to cost estimates from specific disease conditions. The most common 
conditions considered were obesity [37, 44, 45], rheumatoid arthritis [34, 36, 46], migraine [43, 47, 
45] and Ankylosing spondylitis [32, 38, 39] .The majority of the studies were cross-sectional in 
design, but two used information from randomised clinical trials [33, 49]. The majority of studies 
 Value in Health   
were cost-of-illness studies (n=23) and the remaining three studies were all cost-effectiveness 
analyses [33, 49, 50]. 
 
In total, nine instruments measuring presenteeism were identified from the 28 studies. Presenteeism 
was measured by either a study-specific questionnaire or visual analogue scale or an existing 
standardised questionnaire. The most commonly used standard questionnaires were the WPAI (n=6), 
the WLQ (n=5) and Work and Health Interview (WHI) (n=3). Other currently used multi-question 
instruments included the Stanford Presenteeism Scale (SPS) (n=1), HLQ (n=1), PROductivity and 
DISease Questionnaire (PRODISQ) (n=1) and HPQ (n=1). The remaining studies used a self-
constructed global presenteeism question, based on a global response 0 – 10 scale adapted from 
standard questionnaires (n=8). One study used a modified version of the WLQ [51]. 
 
Methods of estimating presenteeism loss  
One of the main prerequisites for including presenteeism in economic evaluations is the ability to 
convert the data collected in the measurement instrument to an estimate of lost productivity. The 
instruments differed in the way they measure the extent of presenteeism loss. The WPAI, HLQ and 
HPQ instruments generated productivity loss estimates that were directly translatable into monetary 
costs, while the estimates from the SPS, WLQ, WHI, PRODISQ and QQ could be indirectly 
quantified into reduced productivity loss with some assumptions. Based on a previous categorisation 
by Mattke et al [20], the estimation of presenteeism in the studies reported was categorised into three 
approaches: direct estimation of productivity loss in hours (19%); estimation of perceived percentage 
loss (77%); and the comparison of productivity loss obtained from an individual with a colleague in a 
similar role (12%).  
The direct approach generates productivity loss values in a similar way to the approach used in 
obtaining absenteeism productivity loss. For example using the WHI, presenteeism loss is estimated 
from a combination of questions such as the average number of hours with low concentration at work, 
when working more slowly than usual, when feeling fatigued at work, and the time in between 
arriving at work and starting work on the days when an employee is sick [44]. Alternatively 
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respondents are asked to estimate the extra hours that would be needed to compensate for inefficient 
hours, a method used by the HLQ [32, 34]. The direct translation approach was found in 5 studies 
(19%). 
The second approach involved asking respondents to provide a perceived overall estimate of how 
much illness has hindered or affected their performance at work. This was the most common approach 
(22 studies (77%)). One productivity loss measurement approach (perceived percentage loss) required 
respondents to provide an estimate of their percentage loss of productivity at work due to illness [43, 
50]. For example articles using the WLQ, obtained an estimate of the percentage presenteeism loss (or 
gain) from respondents compared to a baseline or benchmark value for each Individual [45, 53]. An 
alternative version of this approach involved asking respondents to provide an estimate of how illness 
has affected their performance at work on a 0 –10 scale which was then converted into a percentage 
productivity loss [37, 54]. Studies using the WLQ [36, 38, 45, 53] and SPS [55] also assessed 
perceived limitations in different work function domains and for different work aspects. The output 
from these different domains was then summarised to generate an index which is interpreted as a 
percentage loss attributed to reduced productivity. In the remaining studies, an estimate of perceived 
reduced productivity was estimated using non-standard stand-alone single-item questions as part of a 
wider questionnaire with a global question asking respondents to either estimate perceived 
impairment on a scale of 0-10 or percentage reduction at work due to illness [35, 40, 43, 47, 48, 56, 
57]. Such a question has recently been validated within the context of low back pain [58].  
 
A final approach, used in the Health and Work Performance Questionnaire (HPQ) [33, 34, 42], 
involved comparing global presenteeism estimates of a respondent with those of a colleague in a 
similar role both reported by the respondent. The respondent is asked to report a global rating for an 
average worker on their job, and their usual work performance, alongside a recent performance in 
order to estimate presenteeism related work loss. This is done on a scale of 0 (worst performance at 
work) to 10 (best performance).  
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Methods of valuing presenteeism loss  
Having obtained a measure of productivity loss (such as hours lost, or percentage effort made), this 
metric can then be converted into a monetary estimate. All studies in the review used salary-based 
conversion approaches, more specifically the human capital approach, with the exception of Smit et 
al. [49] who used the friction cost approach. A variety of measures were used to assess the value of 
foregone earnings, and these included: an average wage for all groups (n=11), age-sex dependent 
wage-rates (n=6), and a self-reported gross salary (4) (Table 2). The wage-rates used were expressed 
variously as hourly, daily or annual wage-rates.  
 
Studies were also assessed for whether they considered the impact of presenteeism on output, 
teamwork productivity and substitutability, often known as multiplier effects, and any compensation 
mechanisms [58]. Multiplier effects are additional costs that could result from the negative impact on 
productivity of sick co-workers particularly where team work is involved [60] .Compensation 
mechanisms are adjustments for productivity loss through internal employee substitution mechanisms 
or as a result of ill employees compensating for lost time [61]. These have been reported to have a 
significant impact on overall productivity costs [62]. None of the studies identified adjusted 
presenteeism costs for aspects of compensation mechanisms or included multiplier effects. 
Impact of presenteeism on total costs  
 
Overall nineteen studies (67%) provided enough detail to assess the impact of presenteeism on total 
costs. On average, presenteeism costs comprised 52% (ranging 19% to 85%) of the total costs of the 
interventions or disease conditions investigated (Table 2). The proportion of presenteeism was highest 
in rheumatoid arthritis, back pain and insomnia conditions. A further inspection of studies that did not 
report the overall total costs [32, 37, 43, 53, and 55] showed presenteeism costs were greater than 
absenteeism costs. The three cost-effectiveness studies within this review included productivity losses 
related to presenteeism, but did not provide enough detail to assess the impact of presenteeism on 
cost-effectiveness outcomes [33, 49, and 53].  
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DISCUSSION 
This review assessed the methods used in estimating presenteeism in current practice and the impact 
of presenteeism on total costs of health conditions. In the studies reviewed here, only nine instruments 
were identified in spite of the many existing presenteeism instruments that have been reported in the 
literature. The findings indicated that losses from reduced productivity at work are rarely included in 
cost-effectiveness or cost-utility analyses, although presenteeism has been associated with significant 
costs. Only 3 full economic evaluations (cost-effectiveness or cost-utility analyses) that included 
presenteeism costs were identified in this review [33, 49, and 53]. Understanding of the impact of 
presenteeism is therefore derived largely from cost-of-illness studies. Whilst these show large costs of 
presenteeism resulting from illness, it is less clear what the impact of alternative health interventions 
on presenteeism is likely to be.  
 
Further assessment of the studies revealed a lack of consensus about the most appropriate instruments 
and approaches for measuring and valuing presenteeism. The most common approach used in 
measuring presenteeism was the direct approach which has the advantage of generating directly 
usable productivity output values in lost hours that can easily be valued for use in economic 
evaluations. However, comparisons with other presenteeism approaches suggest this approach 
potentially underestimates lost productivity [63]. These findings are consistent with those of Schultz 
et al., [25] who found wide variations in approaches to monetary valuation for reduced productivity 
among different instruments. Moreover, from the few attempts that have been made to compare across 
measurement instruments within the same population, there is evidence that different instruments 
produced different estimates [23, 63, 64]. High costs were attributed to presenteeism in the studies 
included. It should be noted, however, that the majority of studies used the human capital method 
which is known to overestimate productivity loss; only one study from the Netherlands used the 
friction cost approach to take account of likely re-balance of labour duties in the workplace. Previous 
research has found little or no attempt to apply the friction cost approach in valuing presenteeism [20, 
65]. The proportion of estimates using the human capital approach compared to the friction cost 
approach in this area needs further attention. All studies included in this review were based on 
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subjective measures and therefore are completed by the employee using their own judgement. It 
remains uncertain how these estimates would compare with measures of productivity loss obtained 
from employers.  
 
To date, little evidence exists on presenteeism costs in cost-effectiveness or cost-utility analyses that 
typically inform the process of healthcare decision making. The majority of studies included in this 
review were cost-of-illness studies. There is limited literature on typical economic evaluations 
incorporating presenteeism costs and consequently their impact on overall cost-effectiveness results. 
These findings could be attributed to the studies adhering to national guidelines that in most cases do 
not prescribe inclusion of presenteeism or other related costs such as multiplier effects and 
compensation mechanisms [13]. Another reason could be a general lack of confidence in 
methodology regarding how to measure and value presenteeism. Given that presenteeism contributes 
significantly to overall total costs as has been shown in this review, the exclusion of this cost-category 
in economic evaluations is likely to result in biased societal decision making. 
 
These conclusions need to be considered in light of the strengths and limitations of this study. One 
strength is that the review provides an overview of the instruments and methods used to estimate 
presenteeism in practice. It also comprehensively assesses cost-of-illness studies and economic 
evaluations from various databases showing the impact of presenteeism on total cost of health 
conditions. There were some limitations with the study. Firstly, we used a limited set of databases for 
our search of economic evaluations including presenteeism. As a result, although care was taken to 
include all relevant studies, we could have missed some economic evaluations that considered 
presenteeism.  However, the databases included spanned the health economics, medical and 
behavioural science disciplines and therefore provide a comprehensive overview of the literature. 
Secondly, the selection process in this review did not fully adhere to the cochrane review selection 
process. Notably, the review set out to provide an insight into the current role of productivity costs in 
relation to reduced productivity at work in economic evaluations. It does not seem likely that a more 
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extensive search strategy and selection process would significantly alter the conclusions of this 
review. Finally, studies could have been missed by excluding non-English articles. 
 
In spite of the limitations of this study, some important policy and research implications may be 
drawn. Firstly, there is a need to build a greater awareness about the potential impact of presenteeism-
related conditions on productivity, employers and society in cost-effectiveness or cost-utility analyses 
in order to identify the most effective strategies and interventions of managing these conditions. This 
is particularly important because presenteeism, from this review, appears to contribute significantly to 
productivity costs (or savings) and overall total costs of certain disease areas such as musculoskeletal 
pain, migraine and mental health related disorders. Economic evaluation recommendations in these 
disease conditions that do not include estimates of presenteeism may result in less than optimal 
resource allocation decisions from a societal perspective. Determining the extent to which resource 
allocation is less than optimal is a research area that needs to be prioritised.  In order to do so, 
however, it is clear that there is a need for greater consensus on the methods that should be used to 
estimate presenteeism in economic evaluations. Current proposed cost-effectiveness ratio thresholds 
may not be truly representative of the willingness of society to pay for interventions from a societal 
perspective. Evidence in support of changing current willingness-to-pay thresholds remains 
inconclusive [66, 67] and further research on whether and how to explicitly determine acceptable 
decision making ICER threshold values when incorporating productivity costs in economic evaluation 
would be very helpful. 
 
Previous research has highlighted the role of the friction cost approach in estimating more realistic 
absence related productivity costs compared to the human capital approach, particularly in the long 
run [64]. It is possible that attempts to apply the friction cost approach to generate presenteeism costs 
may lead to more realistic productivity loss estimates than current estimates based on the human 
capital method, as they have in relation to absenteeism [9] . However, the application of this approach 
within the context of presenteeism remains unclear.  Additional evidence is needed to determine how 
to estimate and value presenteeism wage-related multiplier effects and compensation mechanisms at 
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work when estimating productivity costs [62]. The latter issue is particularly important as 
presenteeism costs appear to be greater than those related to absenteeism [44, 52]. Additional research 
is needed to add to this evidence base in these areas.  
 
Finally, a number of measurement instruments have been reported in the literature, although few 
studies have used these productivity instruments to estimate the cost of presenteeism in economic 
evaluation costing practice. The methods used in the instruments varied widely and the impact of the 
alternative estimation approaches on overall cost-effectiveness results needs to be further assessed. 
One way forward is to establish a reference case of standard instruments and corresponding validated 
cost conversion algorithms for estimating the cost of presenteeism. To promote increased 
transparency, a useful practice could be to cross compare instruments and also include a brief 
justification of the instruments chosen (given the number available) with clear reporting of the 
estimation and valuation methods. Although including presenteeism is not feasible for all conditions, 
we would suggest that a first step could be for studies to include presenteeism as a sensitivity or 
secondary care analysis where appropriate to assess the robustness of findings with respect to wider 
costs associated with lost productivity. Also studies that exclude presenteeism costs could justify their 
decision in terms of (ir) relevance to the condition being investigated.   
 
CONCLUSION  
The estimation of reduced productivity at work (presenteeism) seems to be very limited within current 
economic evaluation practice. The development of various presenteeism measurement instruments has 
also not translated into applied costing practice. To enable wider inclusion of presenteeism costs, a 
reference case and guidance regarding standard instruments, methodology for estimating and valuing 
productivity costs related to presenteeism need to be developed. Given the significance of 
presenteeism in relation to lost productivity, and its potential impact on diseases and interventions as 
shown here, more attention needs to be given to the methods used to estimate presenteeism and 
methods for its inclusion in economic evaluations. 
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Table I: Overview of studies included in this review 
Author Country Clinical area Type of study 
Boonen et al.,2010 [32] Netherlands Ankylosing spondylitis COI 
Braakman-Jansen et al .,2012  
[52] 
US Rheumatoid Arthritis COI 
Burton et al.,2002  [48] US Migraine COI 
Burton et al.,2005 [51] US Various health conditions COI 
Cisternas et al., 2003 [56] US Asthma COI 
Collins., 2005 [55] US Chronic conditions COI 
Cooksey et al 2015 [38] UK Ankylosing Spondylitis COI 
Daley et al., 2009  [35] Canada Insomnia COI 
Finkelstein et al., 2010  [37] United Kingdom Obesity COI 
Fishman and Black ,1999 
[47] 
US Migraine COI 
Goetzel et al.,2004 [68] US Various conditions COI 
Goetzel et al.,2010 [45] US Obesity COI 
Hellgren et al.,2010 [40] Sweden Allergic rhinitis and common 
cold. 
COI 
Henke et al.,2000 [69] US PUD and GERD COI 
Hilton et al.,2008 [42] US, UK, 
Australia  
Psychological distress COI 
Lamb et al., 2006 [70] US Allergic Rhinitis COI 
Lerner et al., 2008 [53] US Fibroids CEA 
Li et al., 2006 [36] Canada Arthritis COI 
Linde et al., 2012 [43] 8 European 
countries 
Headache COI 
Rafia et al., 2012 [39] UK Ankylosing spondylitis (AS) COI 
Ricci and Chee, 2005 [44] US Obesity COI 
Smit et al., 2006 [49] Netherlands Depression CEA 
Stewart et al.,2003a [46] US Headache, back pain, Arthritis. COI 
Stewart et al.,2003b [71] US Headache, back pain, Arthritis. COI 
Thavorncharoensap et al., 
2010 [41] 
Thailand Alcohol consequences COI 
Uegaki et al., 2011 [33] Netherlands Maternity CEA 
Wilson et al.,2010 [54] US Acute attacks/ Hereditary COI 
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angioedema (HAE). 
Zhang et al.,2008 [34] Canada Rheumatoid Arthritis COI 
COI, Cost-of-illness; CBA, cost-benefit analysis; CEA, cost-effectiveness analysis; CUA, cost-utility analysis; RCT 
Randomised clinical trial, US United States ; UK United Kingdom 
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Table II: Methods for including presenteeism and overall impact of costs  

















HLQ 2 weeks Average wage HCM Presenteeism 
and 
Absenteeism 
Extra work hour’s 
needed to compensate 
for inefficient hours. 
Direct 
approach 
Annual presenteeism costs: €967; 
Absenteeism €1832 per patient per 
year. % of total NS.  
Braakman-
Jansen et al 
.,2012 [52] 
QQ, WPAI 1 week Average wage-




WPAI: Degree of 
problems affecting 
work productivity  
 
QQ: Quantity and 
quality of work on an 





WPAI; Annual presenteeism costs: 
318(73%) and 72(92%) for 
intervention and control.  
PRODISQ: Annual presenteeism: 299 
(71%) and 154 (95%) for the 



























Modified WLQ  2 weeks NS NS Presenteeism 
only 
% of time the 
respondent was limited 
in performing a 





Annual Presenteeism costs: $1392 to 
$2592 per employee per year.  
Annual Extrapolated to $99M to 
$185M entire population.  















Reduced work hours 




Annual costs: $4912, Indirect costs: 
$1732 (35%). Presenteeism (28%). 
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SPS and WOS  4 weeks National 
average wage-










Annual costs per employee: $6721 for 
Presenteeism. 10% of total productivity 
costs. 6.8% presenteeism. 
Cooksey et al 
[38] 







WPAI: Degree of 
problems affecting 












Annual costs: Absenteeism: £411; 
Presenteeism £3425; Total cost: 
£19,016.  












Extent to which 
insomnia is responsible 
for reduced 





Presenteeism $5 billion (76% of total) 
Total cost $6.6 billion 
Finkelstein et 
al., 2010 [37] 





% reduction in 
productivity and 
estimate of time lost 




Presenteeism ($555 to $3792);  % of 













Degree to which 
headache affects 
normal activities on a 




Presenteeism greater than absenteeism. 
% of total costs NS. 
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Findings (% -  percentage of total 
costs) 












Rate at which 
performance was 





Annual presenteeism:  61% of total 
cost in 10 conditions. 
Goetzel et 
al.,2010 [45] 





% of time the 
respondent was limited 
in performing a 
specific dimension of 





Annual absenteeism and presenteeism 
combined ($2596). Direct costs 
















productivity while at 
work during 




Annual: € 2.7 billion.  





as part of 
interview 
Questionnaire 




Reduced productivity  





Presenteeism: Annual PUD costs per 
year $205 (28% of total), Annual 
GERD $72 (27% of total). 
Hilton et 
al.,2008 [42] 
HPQ 4 weeks Mean Wage-





Self-reported scale of 
performance of 0 to 10 
(worst to best). 
Comparative 
approach 
Annual total costs USD$11.1 billion. 
% of total costs NS. 
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Findings (% -  percentage of total 
costs) 
Australia 










spent at work during 
the recall period. 
Direct 
approach 
% of total costs NS. 
Lerner et al., 
2008 [53] 
WLQ 2 weeks Average wage  HCM Presenteeism 
only 
% of time the 
respondent was limited 
in performing a 
specific dimension of 




Annual Presenteeism: $2341 for 
intervention group; $836 for control 
group. % of total costs NS. 
Li et al., 2006 
[36] 




% of time the 
respondent was limited 
in performing a 
specific dimension of 




Total Annual costs: $11,553 
Presenteeism: $4724 (41% of total 
costs )   
 














Days at work when the 
amount done was ≥ 
50% reduced 
productivity counted as 





Annual  cost per person:  
£ 1222; Presenteeism: £ 765 (63% of 
total costs).  
 
Rafia et al 2012 
[39] 
WPAI 3 months  Average wage HCM Presenteeism 
and 
Absenteeism 
WPAI: Degree of 
problems affecting 






Total 3 month cost of £2,802. 
Absenteeism (1.4%) and presenteeism 
(19%).  
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Findings (% -  percentage of total 
costs) 
Ricci and Chee, 
2005 [44] 







 Self-reported reduced 
work productivity 





Annual cost:  $11.70 billion per year. 
Presenteeism (67% of total costs). 
Smit et al., 
2006 [49] 












Annual presenteeism, intervention: 
€2232(33% of total costs); Annual total 
costs: €6766; Annual presenteeism 
,control: €3175(39% of total costs); 
Annual total costs: €8614; 
Stewart et 
al.,2003a [46] 














Total cost $61.2 billion, presenteeism: 
$46.9 bn (76.6%). Presenteeism for 


















Total productivity costs: $225.8 billion 
per year. On average, presenteeism 
71% of total costs.  
Thavorncharoe














Annual Total costs: $ 9,627 million 
Annual Presenteeism: $ 2,804 million 
(29% total costs). Mortality costs: 
$6,422 million. 
Uegaki et al., 
2011 [33] 




performance due to 
sickness 
Comparative Annual presenteeism, intervention: 
€765(40%); Annual total costs: €1911; 
Annual presenteeism, control: €655 
(38%); Annual total costs: €1734. 
Overall costs, Indirect costs (37%) 
presenteeism (52%). 
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Total costs: $41,992 Indirect Costs: 
$16,108.Absenteeism: 
$3402.Presenteeism $5,750.  

































$30.03, $83.05, $284.07, and $285.10 
(HLQ, WLQ, HPQ, WPAI) over 2 a 
period of weeks.  % of total costs NS. 
NS – not stated, HCM Human capital method, FCA Friction cost approach 
 
